Cargando…

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes

BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority out...

Descripción completa

Detalles Bibliográficos
Autores principales: Riner, Andrea N., Underwood, Patrick W., Yang, Kai, Herremans, Kelly M., Cameron, Miles E., Chamala, Srikar, Qiu, Peihua, George, Thomas J., Permuth, Jennifer B., Merchant, Nipun B., Trevino, Jose G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300394/
https://www.ncbi.nlm.nih.gov/pubmed/32285629
http://dx.doi.org/10.1002/cam4.3042
_version_ 1783547579411202048
author Riner, Andrea N.
Underwood, Patrick W.
Yang, Kai
Herremans, Kelly M.
Cameron, Miles E.
Chamala, Srikar
Qiu, Peihua
George, Thomas J.
Permuth, Jennifer B.
Merchant, Nipun B.
Trevino, Jose G.
author_facet Riner, Andrea N.
Underwood, Patrick W.
Yang, Kai
Herremans, Kelly M.
Cameron, Miles E.
Chamala, Srikar
Qiu, Peihua
George, Thomas J.
Permuth, Jennifer B.
Merchant, Nipun B.
Trevino, Jose G.
author_sort Riner, Andrea N.
collection PubMed
description BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority outcomes are underreported. We hypothesize that outcomes among racially/ethnically diverse PDAC patients may be influenced by treatment facility. METHODS: The National Cancer Database was used to identify 170,327 patients diagnosed with PDAC between 2004 and 2015. Cox proportional‐hazard regression was used to compare survival between race/ethnic groups across facilities. RESULTS: In unadjusted models, compared to non‐Hispanic Whites (NHW), non‐Hispanic Blacks (NHB) had the worst overall survival (HR = 1.05, 95%CI: 1.03‐1.06, P < .001) and Hispanics had the best overall survival (HR = 0.92, 95%CI: 0.90‐0.94, P < .001). After controlling for socioeconomic and clinical covariates, NHB (HR = 0.95, 95%CI: 0.93‐0.96, P < .001) had better overall survival compared to NHW, and Hispanics continued to have the best comparative outcomes (HR = 0.84, 95%CI: 0.82‐0.86, P < .001). Among Hispanics, Dominicans and South/Central Americans lived the longest, at 10.25 and 9.82 months, respectively. The improved survival in Hispanics was most pronounced at ARP (HR = 0.80, 95%CI: 0.77‐0.84, P < .001) and Integrated Network Cancer Programs (HR = 0.78, 95%CI: 0.73‐0.84, P < .001). NHB had improved survival over NHW at Comprehensive Community Care Programs (HR = 0.96, 95%CI: 0.93‐0.98, P = .002) and ARP (HR = 0.96, 95%CI: 0.94‐0.98, P = .001), which was influenced by income, education, and surgical resection. CONCLUSION: Survival was improved at ARP for all populations. Hispanics had the best comparative overall survival. NHB had improved overall survival at higher volume centers, but this was dependent upon income, education, and surgical resection.
format Online
Article
Text
id pubmed-7300394
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73003942020-06-18 Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes Riner, Andrea N. Underwood, Patrick W. Yang, Kai Herremans, Kelly M. Cameron, Miles E. Chamala, Srikar Qiu, Peihua George, Thomas J. Permuth, Jennifer B. Merchant, Nipun B. Trevino, Jose G. Cancer Med Clinical Cancer Research BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority outcomes are underreported. We hypothesize that outcomes among racially/ethnically diverse PDAC patients may be influenced by treatment facility. METHODS: The National Cancer Database was used to identify 170,327 patients diagnosed with PDAC between 2004 and 2015. Cox proportional‐hazard regression was used to compare survival between race/ethnic groups across facilities. RESULTS: In unadjusted models, compared to non‐Hispanic Whites (NHW), non‐Hispanic Blacks (NHB) had the worst overall survival (HR = 1.05, 95%CI: 1.03‐1.06, P < .001) and Hispanics had the best overall survival (HR = 0.92, 95%CI: 0.90‐0.94, P < .001). After controlling for socioeconomic and clinical covariates, NHB (HR = 0.95, 95%CI: 0.93‐0.96, P < .001) had better overall survival compared to NHW, and Hispanics continued to have the best comparative outcomes (HR = 0.84, 95%CI: 0.82‐0.86, P < .001). Among Hispanics, Dominicans and South/Central Americans lived the longest, at 10.25 and 9.82 months, respectively. The improved survival in Hispanics was most pronounced at ARP (HR = 0.80, 95%CI: 0.77‐0.84, P < .001) and Integrated Network Cancer Programs (HR = 0.78, 95%CI: 0.73‐0.84, P < .001). NHB had improved survival over NHW at Comprehensive Community Care Programs (HR = 0.96, 95%CI: 0.93‐0.98, P = .002) and ARP (HR = 0.96, 95%CI: 0.94‐0.98, P = .001), which was influenced by income, education, and surgical resection. CONCLUSION: Survival was improved at ARP for all populations. Hispanics had the best comparative overall survival. NHB had improved overall survival at higher volume centers, but this was dependent upon income, education, and surgical resection. John Wiley and Sons Inc. 2020-04-13 /pmc/articles/PMC7300394/ /pubmed/32285629 http://dx.doi.org/10.1002/cam4.3042 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Riner, Andrea N.
Underwood, Patrick W.
Yang, Kai
Herremans, Kelly M.
Cameron, Miles E.
Chamala, Srikar
Qiu, Peihua
George, Thomas J.
Permuth, Jennifer B.
Merchant, Nipun B.
Trevino, Jose G.
Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title_full Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title_fullStr Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title_full_unstemmed Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title_short Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
title_sort disparities in pancreatic ductal adenocarcinoma—the significance of hispanic ethnicity, subgroup analysis, and treatment facility on clinical outcomes
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300394/
https://www.ncbi.nlm.nih.gov/pubmed/32285629
http://dx.doi.org/10.1002/cam4.3042
work_keys_str_mv AT rinerandrean disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT underwoodpatrickw disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT yangkai disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT herremanskellym disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT cameronmilese disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT chamalasrikar disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT qiupeihua disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT georgethomasj disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT permuthjenniferb disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT merchantnipunb disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes
AT trevinojoseg disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes